Business
Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn®
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":" WOODSTOCK, Ga.--(BUSINESS WIRE)--\nSonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox®, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa.\n\nMicrodox® is a super-oxidized solution based on Sonoma’s patented Microcyn® Technology intended to treat and prevent infections in the urinary tract and bladder. Microdox® is a non-irritating and non-toxic solution and is ready for immediate use. Microdox® is currently available through Sonoma’s partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.\n\n“We believe Microdox® is a unique bladder irrigation that fulfils the requirements of an effective adjunct UTI prevention and treatment for the removal of UTI-causing bacteria, bacterial biofilms and drug-resistant strains,” said Scott Lissington, COO of Te Arai BioFarma.\n\n“We look forward to the benefits that Microdox® will offer in the prevention and treatment of urinary tract infections to health care professionals. This is a revolutionary treatment to patients that have been struggling with complicated, antibiotic resistant and recurrent UTIs,” said Lindsay Shahim, Director of NuAngle.\n\n“We are pleased to bring our partners this new indication for Microdox® that will help reduce urinary tract infections for their patients. Through the science and development of Microcyn® Technology our aim is to improve the quality of life for patients, including those that require a bladder and catheter rinse,” said Bruce Thornton, COO of Sonoma Pharmaceuticals. “Our proprietary Microcyn® technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety.”\n\nAbout Te Arai BioFarma Ltd.\n\nTe Arai BioFarma Limited is a privately owned New Zealand and Australian company specializing in medical devices and specialty medicines. We aim to improve health and productivity through the affordable control and prevention of disease. Te Arai BioFarma is committed to maintaining long term collaborative and innovative relationships with significant global...